|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma显示文摘Hepatocellular carcinoma (HCC) accounts for the majority of primary liver cancers. To date, most patients with HCC are diagnosed at an advanced tumor stage, excluding them from potentially curative therapies (i.e., resection, liver transplantation, percutaneous ablation). Treatments with palliative intent include chemoembolization and systemic therapy. Among systemic treatments, the small-molecule multikinase inhibitor sorafenib has been the only systemic treatment available for advanced HCC over 10 years. More recently, other smallmolecule multikinase inhibitors (e.g., regorafenib, lenvatinib, cabozantinib) have been approved for HCC treatment. The promising immune checkpoint inhibitors (e.g., nivolumab, pembrolizumab) are still under investigation in Europe while in the US nivolumab has already been approved by FDA in sorafenib refractory or resistant patients. Other molecules, such as the selective CDK4/6inhibitors (e.g., palbociclib, ribociclib), are in earlier stages of clinical development, and the c- MET inhibitor tivantinib did not show positive results in a phase III study. However, even if the introduction of targeted agents has led to great advances in patient response and survival with an acceptable toxicity profile, a remarkable inter-individual heterogeneity in therapy outcome persists and constitutes a significant problem in disease management. Thus, the identification of biomarkers that predict which patients will benefit from a specific intervention could significantly affect decision-making and therapy planning. Germ-line variants have been suggested to play an important role in determining outcomes of HCC systemic therapy in terms of both toxicity and treatment efficacy. Particularly, a number of studies have focused on the role of genetic polymorphisms impacting the drug metabolic pathway and membrane translocation as well as the drug mechanism of action as predictive/prognostic markers of HCC treatment. The aim of this review is to summarize and critically discuss the pharmacogenetic literature evidences, with particular attention to sorafenib and regorafenib, which have been used longer than the others in HCC treatment. | Elena De Mattia Erika Cecchin Michela Guardascione Luisa Foltran Tania Di Raimo Francesco Angelini Mario D’Andrea Giuseppe Toffoli | 2019 | World Journal of Gastroenterology2019，25，29： | 8 |
| 2 | Revisiting the Clinical Value of 18F-FDG PET/CT in Detection of Recurrent Epithelial Ovarian Carcinomas: Correlation With Histology, Serum CA-125 Assay, and Conventional Radiological Modalities显示文摘 | Lidija Antunovic Marino Cimitan Eugenio Borsatti Tanja Baresic Roberto Sorio Giorgio Giorda Agostino Steffan Luca Balestreri Rosa Tatta Giovanna Pepe Domenico Rubello Diego Cecchin Vincenzo Canzonieri | 2012 | Clinical Nuclear Medicine2012，，： | 3 |
| 3 | Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment显示文摘 | Elena De Mattia Giuseppe Toffoli Jerry Polesel Mario D’Andrea Giuseppe Corona Vittorina Zagonel Angela Buonadonna Eva Dreussi Erika Cecchin | 2013 | Pharmacogenetics and Genomics2013，，10： | 2 |
| 4 | Short term clinical outcome of patients with acute pulmonary embolism, normal blood pressure and echocardiographic right ventricular dysfunction 显示文摘 | Grifoni S Olivotto L Cecchin P | 2000 | Circulation2000，101，24： | 1 |
| 5 | Effect of pentachlo-rophenol on predator-prey interaction of two rotifers显示文摘 | Gomez A Cecchine G Snell T W | 1997 | Aquatic Toxicology1997，37，： | 1 |
| 6 | A Decentralized Approach for Computing Invariants in Large Scale and Interconnected Petri Nets 显示文摘 | A Bourjij M Boutayeb T Cecchin | 1997 | IEEE1997，，73： | 1 |
| 7 | Pharmacogenetics of irinotecan 显示文摘 | Toffoli G Cecchin E Corona G | 2003 | Curr Med Chem Anticancer Agents2003，3，3： | 1 |
| 8 | Assessing response using 9'mTc-MIBI early after interstitial chemotherapy with carmu- stine-loaded polymers in glioblastoma multiforme: preliminary results显示文摘 | Cecchin D Schiorlin I Della Puppa A | 2014 | Biomed Res Int2014，，68： | 1 |
| 9 | On Generating A Basis of Invariants In Petri Nets 显示文摘 | A Bourjij M Boutayeb T Cecchin | 1997 | IEEE1997，07，80： | 1 |
| 10 | Relief of pruritus and decreases in plasma histamine concentrations during erythropoietin therapy in patients with uremia 显示文摘 | De Marchi S Cecchin E Villalta D | 1992 | N Engl J Med1992，326，： | 1 |
| 11 | Pharmacology of epidermal growth factor inhibitors 显示文摘 | Toffoli G De Mattia E Cecchin E | 2007 | Int J Biol Markers2007，22，1： | 1 |
| 12 | Differentiating anomalous left main coronary artery originating from the pulmonary artery in infants from myocarditis and dilated cardiomyopathy by electrocardiogram显示文摘 | Johnsrude CL Perry JC Cecchin F | 1995 | Am J Cardiol1995，75，1： | 1 |
| 13 | Microvolt Twave altemans with exercise in pediatrics and cogenital heart disease:limitation and predictive value 显示文摘 | Alexander ME Cecchin F Huang KP | 2006 | PACE2006，29，： | 1 |
| 14 | The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer显示文摘 | Toffoli Cecchin G Corona E | 2006 | J Clin Oncol2006，24，19： | 1 |
| 15 | A novel MgCl2- supported Ziegler-Natta catalysts composition :Stereospecific polymerization of propene without external Donor显示文摘 | CECCHIN G MORINI G PELLOCONI A | 2001 | Macromol Symp2001，，173： | 1 |
| 16 | Recommendations and reporta about central venous catheter-related infection显示文摘 | Bacuzzi A Cecchin A Del Bosco A | 2006 | Surg Infect (Larchmt)2006，7，2： | 1 |
| 17 | The electroanatomicmechanisms of atrial tachycardia in patients with tetralogy ofFallot and double outlet right ventricle显示文摘 | Mat DY Alexander ME Cecchin F | 2011 | J Cardiovasc Electro-physiol2011，22，9： | 1 |
| 18 | Analysis of mixtures containing free fatty acids and mono-, di- and triglycerides by high-performance liquid chromatography coupled with evaporative light-scattering detection显示文摘 | Bruno Marcato Giuliano Cecchin | 1996 | Journal of Chromatography1996，730，12： | 1 |
| 19 | Pulmonary valve replacement in tetralogy of Fallot:impact on survival and ventricular tachycardia显示文摘 | Harrild DM Berul CI Cecchin F | | 0，，03： | 1 |
| 20 | Pharmacogenomics and stomach cancer显示文摘 | Toffoli G Cecchin E | 2004 | Pharmacogenomics2004，5，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员